Guocai Tian1,2,3,4, You Fu1,2,3,4, Dahe Zhang1,2,3, Jiang Li5, Zhiyuan Zhang6,7,8,9, Xi Yang10. 1. Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. 2. National Clinical Research Center for Oral Diseases, Shanghai, People's Republic of China. 3. Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, People's Republic of China. 4. Research Unit of Oral and Maxillofacial Regenerative Medicine, Chinese Academy of Medical Sciences, Shanghai, People's Republic of China. 5. Department of Oral Pathology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. 6. Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. zhzhy0502@163.com. 7. National Clinical Research Center for Oral Diseases, Shanghai, People's Republic of China. zhzhy0502@163.com. 8. Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, People's Republic of China. zhzhy0502@163.com. 9. Research Unit of Oral and Maxillofacial Regenerative Medicine, Chinese Academy of Medical Sciences, Shanghai, People's Republic of China. zhzhy0502@163.com. 10. Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. yangxi112015@sina.com.cn.
Abstract
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is a common tumor worldwide with poor prognosis. The pathogenesis of human papillomavirus (HPV)-positive and HPV-negative HNSCCs differs. However, few studies have considered the HPV status when identifying biomarkers for HNSCC. Thus, the identification of biomarkers for HPV-positive and HPV-negative HNSCCs is urgently needed. METHODS: Three microarray datasets from Gene Expression Omnibus (GEO) were analyzed, and the differentially expressed genes (DEGs) were obtained. Then, functional enrichment pathway analysis was performed and protein-protein interaction (PPI) networks were constructed. The expression of hub genes at both the mRNA and protein level was determined in Oncomine, The Cancer Genome Atlas (TCGA) and the Human Protein Atlas (HPA). In addition, survival analysis of the patient stratified by HPV status and the expression levels of key genes were performed based on TCGA data. The role of AREG, STAG3, CAV1 and C19orf57 in cancer were analyzed through Gene set enrichment analysis (GSEA). The top ten small molecule drugs were identified and the therapeutic value of zonisamide, NVP-AUY922, PP-2 and fostamatinib was further evaluated in six HPV-negative HNSCC cell lines. Finally, the therapeutic value of NVP-AUY922 was tested in vivo based on three HPV-negative HNSCC models, and statistical analysis was performed. RESULTS: In total, 47 DEGs were obtained, 11 of which were identified as hub genes. Biological process analysis indicated that the hub genes were associated with the G1/S transition of the mitotic cell cycle. Survival analysis uncovered that the prognostic value of AREG, STAG3, C19orf57 and CAV1 differed between HPV-positive and HPV-negative patients. Gene set enrichment analysis (GSEA) showed the role of AREG, STAG3 and CAV1 in dysregulated pathways of tumor. Ten small molecules were identified as potential drugs specifically for HPV-positive or HPV-negative patients; three-NVP-AUY922, fostamatinib and PP-2-greatly inhibited the proliferation of six HPV-negative HNSCC cell lines in vitro, and NVP-AUY922 inhibited three HPV-negative HNSCC xenografts in vivo. CONCLUSIONS: In conclusion, AREG, STAG3, C19orf57 and CAV1 are key prognostic factors and potential therapeutic targets in HPV-negative HNSCC. NVP-AUY922, fostamatinib and PP-2 may be effective drugs for HPV-negative HNSCC.
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is a common tumor worldwide with poor prognosis. The pathogenesis of human papillomavirus (HPV)-positive and HPV-negative HNSCCs differs. However, few studies have considered the HPV status when identifying biomarkers for HNSCC. Thus, the identification of biomarkers for HPV-positive and HPV-negative HNSCCs is urgently needed. METHODS: Three microarray datasets from Gene Expression Omnibus (GEO) were analyzed, and the differentially expressed genes (DEGs) were obtained. Then, functional enrichment pathway analysis was performed and protein-protein interaction (PPI) networks were constructed. The expression of hub genes at both the mRNA and protein level was determined in Oncomine, The Cancer Genome Atlas (TCGA) and the Human Protein Atlas (HPA). In addition, survival analysis of the patient stratified by HPV status and the expression levels of key genes were performed based on TCGA data. The role of AREG, STAG3, CAV1 and C19orf57 in cancer were analyzed through Gene set enrichment analysis (GSEA). The top ten small molecule drugs were identified and the therapeutic value of zonisamide, NVP-AUY922, PP-2 and fostamatinib was further evaluated in six HPV-negative HNSCC cell lines. Finally, the therapeutic value of NVP-AUY922 was tested in vivo based on three HPV-negative HNSCC models, and statistical analysis was performed. RESULTS: In total, 47 DEGs were obtained, 11 of which were identified as hub genes. Biological process analysis indicated that the hub genes were associated with the G1/S transition of the mitotic cell cycle. Survival analysis uncovered that the prognostic value of AREG, STAG3, C19orf57 and CAV1 differed between HPV-positive and HPV-negative patients. Gene set enrichment analysis (GSEA) showed the role of AREG, STAG3 and CAV1 in dysregulated pathways of tumor. Ten small molecules were identified as potential drugs specifically for HPV-positive or HPV-negative patients; three-NVP-AUY922, fostamatinib and PP-2-greatly inhibited the proliferation of six HPV-negative HNSCC cell lines in vitro, and NVP-AUY922 inhibited three HPV-negative HNSCC xenografts in vivo. CONCLUSIONS: In conclusion, AREG, STAG3, C19orf57 and CAV1 are key prognostic factors and potential therapeutic targets in HPV-negative HNSCC. NVP-AUY922, fostamatinib and PP-2 may be effective drugs for HPV-negative HNSCC.
Entities:
Keywords:
Biomarker; Head and neck squamous cell carcinoma; Human papillomavirus; NVP-AUY922; Prognosis; Small molecule drugs
Authors: Scott V Bratman; Jeffrey P Bruce; Brian O'Sullivan; Trevor J Pugh; Wei Xu; Kenneth W Yip; Fei-Fei Liu Journal: JAMA Oncol Date: 2016-06-01 Impact factor: 31.777
Authors: Daniella Karassawa Zanoni; Pablo H Montero; Jocelyn C Migliacci; Jatin P Shah; Richard J Wong; Ian Ganly; Snehal G Patel Journal: Oral Oncol Date: 2019-02-15 Impact factor: 5.337
Authors: Swati Tomar; Christian A Graves; Diego Altomare; Sangeeta Kowli; Susannah Kassler; Natalie Sutkowski; M Boyd Gillespie; Kim E Creek; Lucia Pirisi Journal: Head Neck Date: 2015-06-15 Impact factor: 3.147
Authors: William M Lydiatt; Snehal G Patel; Brian O'Sullivan; Margaret S Brandwein; John A Ridge; Jocelyn C Migliacci; Ashley M Loomis; Jatin P Shah Journal: CA Cancer J Clin Date: 2017-01-27 Impact factor: 508.702
Authors: Michaela K Keck; Zhixiang Zuo; Arun Khattri; Thomas P Stricker; Christopher D Brown; Matin Imanguli; Damian Rieke; Katharina Endhardt; Petra Fang; Johannes Brägelmann; Rebecca DeBoer; Mohamed El-Dinali; Serdal Aktolga; Zhengdeng Lei; Patrick Tan; Steve G Rozen; Ravi Salgia; Ralph R Weichselbaum; Mark W Lingen; Michael D Story; K Kian Ang; Ezra E W Cohen; Kevin P White; Everett E Vokes; Tanguy Y Seiwert Journal: Clin Cancer Res Date: 2014-12-09 Impact factor: 12.531
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Vonn Walter; Xiaoying Yin; Matthew D Wilkerson; Christopher R Cabanski; Ni Zhao; Ying Du; Mei Kim Ang; Michele C Hayward; Ashley H Salazar; Katherine A Hoadley; Karen Fritchie; Charles J Sailey; Charles G Sailey; Mark C Weissler; William W Shockley; Adam M Zanation; Trevor Hackman; Leigh B Thorne; William D Funkhouser; Kenneth L Muldrew; Andrew F Olshan; Scott H Randell; Fred A Wright; Carol G Shores; D Neil Hayes Journal: PLoS One Date: 2013-02-22 Impact factor: 3.240
Authors: Lorenzo Lo Muzio; Andrea Ballini; Stefania Cantore; Lucrezia Bottalico; Ioannis Alexandros Charitos; Mariateresa Ambrosino; Riccardo Nocini; Annarita Malcangi; Mario Dioguardi; Angela Pia Cazzolla; Edoardo Brauner; Luigi Santacroce; Michele Di Cosola Journal: Biomed Res Int Date: 2021-11-02 Impact factor: 3.411